Brachytherapy Benefits in High-Risk Prostate CancerBrachytherapy Benefits in High-Risk Prostate Cancer
Brachytherapy after external beam radiotherapy (EBRT) doubles the chance of progression-free survival at 9 years when compared with EBRT alone. Medscape Medical News
Radiation treatment (RT) is an effective option for men with localized prostate cancer (PCa). However, local recurrences (LR) remain common in patients treated with external beam radiotherapy (EBRT) alone. Dose-escalated RT to the whole gland (WG) has demonstrated increased locoregional and biochemical control in localized PCa.[3-5] A meta-analysis concluded that each 1-Gray (Gy) increased in dose delivered reduces 1.8% the risk of biochemical failure. Nevertheless, concerns have been raised with regards to increased toxicity and subsequently worsening the quality of life (QoL) of patients treated with dose escalation.
Authors: Konat-Bąska K, Chicheł A, Staszek-Szewczyk U, Maciejczyk A, Matkowski R Abstract Purpose: Prostate and colorectal cancers are the first and the third most popular malignancies in male population, in which some patients may develop these tumors metachronously or synchronously. At present, there are no standard recommendations, and oncologists need to provide an optimal management for two different cancers with an acceptable risk of possible treatment of adverse effects. Material and methods: This case report presents the treatment of a 61-year-old patient suffering from synchronous prostate and rectal...
In the results section of the abstract of the above-referenced article, the sentence “Most men had T1 disease (62%) and Gleason score
Since post-treatment PSA values were first introduced into clinical practice in the 1980s, clinicians have grappled with interpretation of these values. Two consensus conferences, ASTRO in 1996  and Phoenix in 2005 , defined biochemical failure after external beam radiotherapy (EBRT), but neither included data from patients treated with androgen deprivation therapy (ADT) or brachytherapy . Neither consensus conference attempted to define cure and neither definition is readily comparable to a surgical definition of failure.
This study evaluates acute patient-reported bowel quality of life (QOL) and rectal bleeding in prostate cancer patients treated with combination external beam radiation (EBRT), low-dose-rate brachytherapy (LDR-BT), and SpaceOAR.
To assess the correlation between postimplant dosimetric quantifiers and the genitourinary (GU) toxicity of low-dose rate brachytherapy for prostate cancer.
Men with Gleason grade Group (GG) 4 and 5 prostate cancer have high failure rates when treated by conventional therapy. We investigated the effect of higher radiation doses on freedom from biochemical failure (FBF) and prostate cancer mortality (cause-specific survival [CSS]) in men treated with a combination of permanent implant and external beam irradiation (EBRT).
High dose-rate (HDR) brachytherapy is commonly administered as a boost to external beam radiation therapy (EBRT). Our purpose was to compare toxicity with increasingly hypofractionated EBRT in combination with a single 15 Gy HDR boost for men with intermediate-risk prostate cancer.
Conclusions: This study highlights excellent outcomes for intermediate-risk prostate cancer patients, including unfavorable intermediate-risk cases, treated with BED ≥ 200 Gy radiotherapy using LDR brachytherapy. LDR alone with a BED of 200 Gy may be an optimal treatment for both favorable and unfavorable intermediate-risk prostate cancer patients, although a longer follow-up is mandatory to confirm the present findings. PMID: 32190064 [PubMed]
Conclusions: The excellent long-term results and low morbidity presented as well as many advantages of prostate brachytherapy over other treatments demonstrates that brachytherapy is an effective treatment for patients with transurethral resection and organ-confined prostate cancer. PMID: 32190063 [PubMed]